These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39222148)

  • 1. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.
    Yoshimura A; Kato T; Nakai Y; Tsujihata M; Toyoda S; Sato M; Matsuzaki K; Nakata W; Takao T; Inoguchi S; Okuda Y; Yamamichi G; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Takada S; Inoue H; Nishimura K; Miyake O; Fujita K; Nakayama M; Nishimura K; Nonomura N
    Int J Clin Oncol; 2024 Dec; 29(12):1916-1924. PubMed ID: 39222148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Tanaka H; Makiguchi T; Tozuka T; Kawashima Y; Oba T; Tsugitomi R; Koyama J; Tambo Y; Ogusu S; Saiki M; Gyotoku H; Hasegawa T; Miyauchi E; Sonoda T; Saito R; Nakatomi K; Sakatani T; Kudo K; Tsuchiya-Kawano Y; Nishio M
    Eur J Cancer; 2024 Dec; 213():115117. PubMed ID: 39522333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.
    Majidova N; Seyyar M; Bayraktar DI; Dinç G; İsgandarov E; Huseynov J; Yaşar A; Çelebi A; Sever N; Kocaaslan E; Erel P; Ağyol Y; Güren AK; Arıkan R; Işık S; Ercelep Ö; Demirağ G; Kefeli U; Köstek O; Bayoğlu İV; Sarı M
    Biomol Biomed; 2024 Oct; 24(6):1776-1784. PubMed ID: 38920621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
    Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T
    Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Tsuboi I; Matsukawa A; Kardoust Parizi M; Miszczyk M; Fazekas T; Schulz RJ; Mancon S; Litterio G; Laukhtina E; Kawada T; Katayama S; Iwata T; Bekku K; Rajwa P; Wada K; Karakiewicz PI; Araki M; Shariat SF
    Clin Genitourin Cancer; 2024 Dec; 22(6):102237. PubMed ID: 39546952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
    Gebrael G; Meza L; Li X; Zengin Z; Sayegh N; Ebrahimi H; Tripathi N; Castro D; Mercier B; Barragan-Carrillo R; Li H; Chehrazi-Raffle A; Swami U; Tripathi A; Agarwal N; Maughan BL; Pal SK
    Eur Urol Focus; 2024 Sep; 10(5):812-817. PubMed ID: 38580524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).
    Enrico D; Gomez JE; Aguirre D; Tissera NS; Tsou F; Pupareli C; Tanco DP; Waisberg F; Rodríguez A; Rizzo M; Minatta N; Rafael P; Basbus L; Lupinacci L; Kaen D; Ramos M; Bluthgen V; Castagneris N; Coppola MP; Scocimarro A; Guerra MF; Perfetti A; Levit P; Galvez-Nino M; Mas L; Rojas L; Zuluaga J; Chacón M; Corrales L; Samtani S; Arrieta O; Cardona A; Remon J; Martín C
    Clin Lung Cancer; 2024 Dec; 25(8):723-731.e2. PubMed ID: 39424512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
    Ornstein MC; George L; Wei W; Diaz-Montero CM; Rayman P; Martin A; Basu A; Beckermann KE; Nizam A; Wee CE; Gilligan TD; Gupta S; Rini BI
    Clin Genitourin Cancer; 2024 Dec; 22(6):102181. PubMed ID: 39208489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Hassler MR; Moedlagl V; Hindinger H; Krauter J; Klager S; Resch I; Huebner N; Yurdakul O; Ofner H; Korn SM; D'Andrea D; Gust K; Shariat SF
    Eur Urol Focus; 2024 Sep; 10(5):779-787. PubMed ID: 38161107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD007807. PubMed ID: 28752910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.